Triamcinolone acetonide (Zilretta): Difference between revisions
No edit summary |
No edit summary |
||
Line 245: | Line 245: | ||
(Description) | (Description) | ||
|drugBox={{Drugbox2 | |drugBox={{Drugbox2 | ||
| verifiedrevid = | | Verifiedfields = changed | ||
| IUPAC_name = | | Watchedfields = changed | ||
| image = | | verifiedrevid = 470613003 | ||
| | | IUPAC_name = (4a''S'',4b''R'',5''S'',6a''S'',6b''S'',9a''R'',10a''S'',10b''S'')-4b-fluoro-6b-glycoloyl-5-hydroxy-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2''H''-naphtho[2',1':4,5]indeno[1,2-''d''][1,3]dioxol-2-one | ||
| image = zilrettawiki.png | |||
| width = 250px | |||
<!--Clinical data--> | <!--Clinical data--> | ||
| tradename = | | tradename = | ||
| | | pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> | ||
| | | pregnancy_US = <!-- A / B / C / D / X --> | ||
| | | pregnancy_category = | ||
| | | legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --> | ||
| legal_CA = | |||
| legal_UK = | |||
| legal_US = | |||
| legal_status = | | legal_status = | ||
| routes_of_administration = | | routes_of_administration = [[Topical medication|Topical]], [[joint injection]] | ||
<!--Pharmacokinetic data--> | <!--Pharmacokinetic data--> | ||
| bioavailability = | | bioavailability = | ||
| protein_bound = | |||
| metabolism = | | metabolism = | ||
| elimination_half-life = | | elimination_half-life = | ||
| excretion = | | excretion = | ||
<!--Identifiers--> | <!-- Identifiers --> | ||
| CAS_number_Ref = | | CAS_number_Ref = {{cascite|correct|CAS}} | ||
| CAS_number = | | CAS_number = 76-25-5 | ||
| CAS_supplemental = | |||
| class = | |||
| ATC_prefix = | | ATC_prefix = | ||
| ATC_suffix = | | ATC_suffix = | ||
| PubChem = | | ATC_supplemental = | ||
| IUPHAR_ligand = | | PubChem = 6436 | ||
| IUPHAR_ligand = 2867 | |||
| DrugBank_Ref = | | DrugBank_Ref = | ||
| DrugBank = | | DrugBank = | ||
| ChemSpiderID_Ref = | | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ||
| ChemSpiderID = | | ChemSpiderID = 6196 | ||
| UNII_Ref = | | UNII_Ref = {{fdacite|correct|FDA}} | ||
| UNII = | | UNII = F446C597KA | ||
| KEGG = | | KEGG = | ||
| ChEBI_Ref = | | ChEBI_Ref = {{ebicite|changed|EBI}} | ||
| ChEBI = | | ChEBI = 71418 | ||
| ChEMBL_Ref = | | ChEMBL_Ref = {{ebicite|correct|EBI}} | ||
| ChEMBL = | | ChEMBL = 1504 | ||
| synonyms = <small>9α-Fluoro-16α-17α-isopropyledenedioxyprednisolone; 9α-Fluoro-16α-hydroxyprednisolone 16α,17α-acetonide; 9α-Fluoro-11β,16α-17α,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with acetone; 9α-Fluoro-11β,21-dihydroxy-16α,17α-isopropylidenedioxypregna-1,4-diene,3,20-dione</small> | |||
<!--Chemical data--> | <!--Chemical data--> | ||
| C= | H= | | | C=24 | H=31 | F=1 | O=6 | ||
| molecular_weight = | | molecular_weight = 434.504 g/mol | ||
| | | SMILES = C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)CO)CCC5=CC(=O)C=C[C@@]53C)F)O | ||
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} | |||
| StdInChI = 1S/C24H31FO6/c1-20(2)30-19-10-16-15-6-5-13-9-14(27)7-8-21(13,3)23(15,25)17(28)11-22(16,4)24(19,31-20)18(29)12-26/h7-9,15-17,19,26,28H,5-6,10-12H2,1-4H3/t15-,16-,17-,19+,21-,22-,23-,24+/m0/s1 | |||
| StdInChI_Ref = | | StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | ||
| StdInChI = | | StdInChIKey = YNDXUCZADRHECN-JNQJZLCISA-N | ||
| StdInChIKey_Ref = | |||
| StdInChIKey = | |||
}} | }} | ||
|mechAction= | |mechAction= | ||
|structure= | *Triamcinolone acetonide is a corticosteroid with anti-inflammatory and immunomodulating properties. It binds to and activates the glucocorticoid receptor, leading to activation of anti-inflammatory transcription factors such as lipocortins and inhibition of inflammatory transduction pathways by blocking the release of arachidonic acid and preventing the synthesis of prostaglandins and leukotrienes. | ||
|PD=( | |structure= | ||
|PK=( | [[image:zilrettastructure.png|none|thumb|400px|This image is provided by the National Library of Medicine.]] | ||
|nonClinToxic= | |PD= | ||
*Studies indicate that following a single intramuscular dose of 60 to 100 mg of immediate-release triamcinolone acetonide injectable suspension, adrenal suppression occurs within 24 to 48 hours and then gradually returns to normal, usually in 30 to 40 days. To assess potential effects of the systemic levels of triamcinolone acetonide associated with a single intra-articular (IA) administration of ZILRETTA on hypothalamic pituitary adrenal (HPA) axis function, serum and urine cortisol levels were monitored over 6 weeks post injection. Adrenal suppression with ZILRETTA occurred within 12-24 hours and then gradually returned to normal, within 30-42 days. | |||
*Corticosteroids may increase blood glucose concentrations. | |||
*In a study where 18 patients with osteoarthritis knee pain and controlled type 2 diabetes mellitus received a single IA injection of ZILRETTA into the knee, the change from baseline in average blood glucose over the 72 hours after injection as measured by a continuous glucose monitoring device was 8.2 mg/dL (95% confidence interval 0.1, 29.2). | |||
|PK= | |||
===== | *ZILRETTA is an extended-release dosage form consisting of microspheres of poly(lactic-co-glycolic acid) (PLGA) containing triamcinolone acetonide. Plasma pharmacokinetic parameters for triamcinolone acetonide following IA administration of ZILRETTA or 40 mg immediate-release triamcinolone acetonide into the knee are provided in TABLE 4. | ||
[[image:zilrettapk.png|none|thumb|400px|This image is provided by the National Library of Medicine.]] | |||
|nonClinToxic= | |||
=====Carcinogenesis, Mutagenesis, Impairment of Fertility===== | |||
===== | =====Carcinogenesis===== | ||
*Long-term animal studies to evaluate the carcinogenic potential of ZILRETTA have not been conducted. | |||
( | =====Mutagenesis===== | ||
*Adequate mutagenicity studies have not been conducted with ZILRETTA. | |||
=====Impairment of Fertility===== | |||
*Studies in animals to evaluate the impairment of fertility of ZILRETTA have not been conducted. | |||
|clinicalStudies= | |||
*The efficacy of ZILRETTA was demonstrated in a multi-center, international, randomized, double-blind, parallel-arm, placebo- and active-controlled study in patients with osteoarthritis pain of the knee. A total of 484 patients (ZILRETTA 32 mg, N=161; placebo [saline], N=162; active control [a crystalline suspension, immediate-release formulation of triamcinolone acetonide 40 mg], N=161) were treated and followed for up to 24 weeks. Patients had a mean age of 62 (range 40 to 85 years); baseline demographics and disease characteristics were balanced across treatment arms. Twenty-five percent (25%) of patients had received at least one prior corticosteroid intra-articular injection more than 3 months prior to treatment. A total of 470 patients (97%) completed follow-up to Week 12, the time point for primary efficacy determination, and 443 (91.5%) completed to Week 24. | |||
*The primary efficacy endpoint comparing ZILRETTA to placebo was change from baseline at Week 12 in the weekly mean of the Average Daily Pain intensity scores (ADP) as assessed by a 0-10 Numeric Rating Scale (NRS). ZILRETTA demonstrated a statistically significant reduction in pain intensity at the primary endpoint vs placebo. ZILRETTA also demonstrated a reduction in pain intensity scores each week from Weeks 1 through 12 ( FIGURE 1). | |||
*In a secondary exploratory analysis, statistical significance was not demonstrated between the ZILRETTA and the active control (immediate-release triamcinolone acetonide) treatment groups for the change from baseline at Week 12 in weekly mean ADP. | |||
[[image:zilrettatrial1.png|none|thumb|400px|This image is provided by the National Library of Medicine.]] | |||
|howSupplied= | |howSupplied= | ||
[[image:zilrettasupply.png|none|thumb|400px|This image is provided by the National Library of Medicine.]] | [[image:zilrettasupply.png|none|thumb|400px|This image is provided by the National Library of Medicine.]] |
Revision as of 12:57, 31 July 2018
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sonya Gelfand
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Black Box Warning
Warning Title
See full prescribing information for complete Boxed Warning.
Condition Name: (Content)
|
Overview
Triamcinolone acetonide (Zilretta) is a Acetylcholine release inhibitor, Adrenergic receptor agonist that is FDA approved for the (type of indication of drug) of a list of indications, separated by commas.. There is a Black Box Warning for this drug as shown here. Common adverse reactions include a list of adverse reactions, separated by commas..
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
Condition 1
- Dosing Information
- (Dosage)
Condition 2
- Dosing Information
- (Dosage)
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
Condition 1
- Developed by: (Organisation)
- Class of Recommendation: (Class) (Link)
- Strength of Evidence: (Category A/B/C) (Link)
- Dosing Information/Recommendation
- (Dosage)
Condition 2
- Developed by: (Organisation)
- Class of Recommendation: (Class) (Link)
- Strength of Evidence: (Category A/B/C) (Link)
- Dosing Information/Recommendation
- (Dosage)
Non–Guideline-Supported Use
Condition 1
- Dosing Information
- (Dosage)
Condition 2
- Dosing Information
- (Dosage)
Condition 3
- Dosing Information
- (Dosage)
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
Condition 1
- Dosing Information
- (Dosage)
Condition 2
- Dosing Information
- (Dosage)
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
Condition 1
- Developed by: (Organisation)
- Class of Recommendation: (Class) (Link)
- Strength of Evidence: (Category A/B/C) (Link)
- Dosing Information/Recommendation
- (Dosage)
Condition 2
- Developed by: (Organisation)
- Class of Recommendation: (Class) (Link)
- Strength of Evidence: (Category A/B/C) (Link)
- Dosing Information/Recommendation
- (Dosage)
Non–Guideline-Supported Use
Condition 1
- Dosing Information
- (Dosage)
Condition 2
- Dosing Information
- (Dosage)
Condition 3
- Dosing Information
- (Dosage)
Contraindications
CONTRAINDICATIONS
Warnings
Warning Title
See full prescribing information for complete Boxed Warning.
Condition Name: (Content)
|
Conidition 1
(Description)
Conidition 2
(Description)
Conidition 3
(Description)
Adverse Reactions
Clinical Trials Experience
Central Nervous System
- (list/description of adverse reactions)
Cardiovascular
- (list/description of adverse reactions)
Respiratory
- (list/description of adverse reactions)
Gastrointestinal
- (list/description of adverse reactions)
Hypersensitive Reactions
- (list/description of adverse reactions)
Miscellaneous
- (list/description of adverse reactions)
Condition 2
Central Nervous System
- (list/description of adverse reactions)
Cardiovascular
- (list/description of adverse reactions)
Respiratory
- (list/description of adverse reactions)
Gastrointestinal
- (list/description of adverse reactions)
Hypersensitive Reactions
- (list/description of adverse reactions)
Miscellaneous
- (list/description of adverse reactions)
Postmarketing Experience
(Description)
Drug Interactions
- Drug 1
- Drug 2
- Drug 3
- Drug 4
- Drug 5
Drug 1
(Description)
Drug 2
(Description)
Drug 3
(Description)
Drug 4
(Description)
Drug 5
(Description)
Use in Specific Populations
Pregnancy
Pregnancy Category (FDA):
(Description)
Pregnancy Category (AUS):
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Triamcinolone acetonide (Zilretta) in women who are pregnant.
Labor and Delivery
(Description)
Nursing Mothers
(Description)g
Pediatric Use
(Description)
Geriatic Use
(Description)
Gender
(Description)
Race
(Description)
Renal Impairment
(Description)
Hepatic Impairment
(Description)
Females of Reproductive Potential and Males
(Description)
Immunocompromised Patients
(Description)
Others
(Description)
Administration and Monitoring
Administration
(Oral/Intravenous/etc)
Monitoring
Condition 1
(Description regarding monitoring, from Warnings section)
Condition 2
(Description regarding monitoring, from Warnings section)
Condition 3
(Description regarding monitoring, from Warnings section)
IV Compatibility
There is limited information regarding the compatibility of Triamcinolone acetonide (Zilretta) and IV administrations.
Overdosage
Acute Overdose
Signs and Symptoms
(Description)
Management
(Description)
Chronic Overdose
Signs and Symptoms
(Description)
Management
(Description)
Pharmacology
![]() | |
Triamcinolone acetonide (Zilretta)
| |
Systematic (IUPAC) name | |
(4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS)-4b-fluoro-6b-glycoloyl-5-hydroxy-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one | |
Identifiers | |
CAS number | |
ATC code | ? |
PubChem | |
Chemical data | |
Formula | Template:OrganicBox atomTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox |
Mol. mass | 434.504 g/mol |
Synonyms | 9α-Fluoro-16α-17α-isopropyledenedioxyprednisolone; 9α-Fluoro-16α-hydroxyprednisolone 16α,17α-acetonide; 9α-Fluoro-11β,16α-17α,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with acetone; 9α-Fluoro-11β,21-dihydroxy-16α,17α-isopropylidenedioxypregna-1,4-diene,3,20-dione |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | ? |
Half life | ? |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | Topical, joint injection |
Mechanism of Action
- Triamcinolone acetonide is a corticosteroid with anti-inflammatory and immunomodulating properties. It binds to and activates the glucocorticoid receptor, leading to activation of anti-inflammatory transcription factors such as lipocortins and inhibition of inflammatory transduction pathways by blocking the release of arachidonic acid and preventing the synthesis of prostaglandins and leukotrienes.
Structure
![](/images/d/dc/Zilrettastructure.png)
Pharmacodynamics
- Studies indicate that following a single intramuscular dose of 60 to 100 mg of immediate-release triamcinolone acetonide injectable suspension, adrenal suppression occurs within 24 to 48 hours and then gradually returns to normal, usually in 30 to 40 days. To assess potential effects of the systemic levels of triamcinolone acetonide associated with a single intra-articular (IA) administration of ZILRETTA on hypothalamic pituitary adrenal (HPA) axis function, serum and urine cortisol levels were monitored over 6 weeks post injection. Adrenal suppression with ZILRETTA occurred within 12-24 hours and then gradually returned to normal, within 30-42 days.
- Corticosteroids may increase blood glucose concentrations.
- In a study where 18 patients with osteoarthritis knee pain and controlled type 2 diabetes mellitus received a single IA injection of ZILRETTA into the knee, the change from baseline in average blood glucose over the 72 hours after injection as measured by a continuous glucose monitoring device was 8.2 mg/dL (95% confidence interval 0.1, 29.2).
Pharmacokinetics
- ZILRETTA is an extended-release dosage form consisting of microspheres of poly(lactic-co-glycolic acid) (PLGA) containing triamcinolone acetonide. Plasma pharmacokinetic parameters for triamcinolone acetonide following IA administration of ZILRETTA or 40 mg immediate-release triamcinolone acetonide into the knee are provided in TABLE 4.
![](/images/c/c7/Zilrettapk.png)
Nonclinical Toxicology
Carcinogenesis, Mutagenesis, Impairment of Fertility
Carcinogenesis
- Long-term animal studies to evaluate the carcinogenic potential of ZILRETTA have not been conducted.
Mutagenesis
- Adequate mutagenicity studies have not been conducted with ZILRETTA.
Impairment of Fertility
- Studies in animals to evaluate the impairment of fertility of ZILRETTA have not been conducted.
Clinical Studies
- The efficacy of ZILRETTA was demonstrated in a multi-center, international, randomized, double-blind, parallel-arm, placebo- and active-controlled study in patients with osteoarthritis pain of the knee. A total of 484 patients (ZILRETTA 32 mg, N=161; placebo [saline], N=162; active control [a crystalline suspension, immediate-release formulation of triamcinolone acetonide 40 mg], N=161) were treated and followed for up to 24 weeks. Patients had a mean age of 62 (range 40 to 85 years); baseline demographics and disease characteristics were balanced across treatment arms. Twenty-five percent (25%) of patients had received at least one prior corticosteroid intra-articular injection more than 3 months prior to treatment. A total of 470 patients (97%) completed follow-up to Week 12, the time point for primary efficacy determination, and 443 (91.5%) completed to Week 24.
- The primary efficacy endpoint comparing ZILRETTA to placebo was change from baseline at Week 12 in the weekly mean of the Average Daily Pain intensity scores (ADP) as assessed by a 0-10 Numeric Rating Scale (NRS). ZILRETTA demonstrated a statistically significant reduction in pain intensity at the primary endpoint vs placebo. ZILRETTA also demonstrated a reduction in pain intensity scores each week from Weeks 1 through 12 ( FIGURE 1).
- In a secondary exploratory analysis, statistical significance was not demonstrated between the ZILRETTA and the active control (immediate-release triamcinolone acetonide) treatment groups for the change from baseline at Week 12 in weekly mean ADP.
![](/images/3/37/Zilrettatrial1.png)
How Supplied
![](/images/4/4a/Zilrettasupply.png)
Storage
- To maintain expiry period, refrigerate the ZILRETTA single-dose kit (36°-46°F; 2°-8°C) before use.
- If refrigeration is unavailable, store the ZILRETTA single-dose kit in the sealed, unopened kit at temperatures not exceeding 77°F (25°C) for up to six weeks and then discard. Do not expose the ZILRETTA single-dose kit to temperatures above 77°F (25°C).
- Do not freeze. Store vials in carton.
Images
Drug Images
{{#ask: Page Name::Triamcinolone acetonide (Zilretta) |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
![](/images/2/27/Zilrettalabel1.jpeg)
![](/images/f/f5/Zilrettalabel2.jpeg)
![](/images/d/d4/Zilrettalabel3.jpeg)
![](/images/6/6d/Zilrettalabel4.jpeg)
![](/images/0/03/Zilrettalabel5.jpeg)
![](/images/0/0e/Zilrettalabel6.jpeg)
{{#ask: Label Page::Triamcinolone acetonide (Zilretta) |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
Increased Risk of Infections
- Inform patients that they may be more likely to develop infections when taking corticosteroids. Instruct patients to contact their health care provider if they develop fever or other signs or symptoms of infection.
- Advise patients who have not been vaccinated to avoid exposure to chicken pox or measles. Instruct patients to contact their health care provider immediately if they are exposed.
Risk of Drug Interactions
- There are a number of medicines that can interact with corticosteroids such as triamcinolone acetonide. Advise patients to alert their health care provider(s) to assess the need to adjust their medication(s).
Risk of Adverse Psychiatric Reactions
- Inform patients that corticosteroid use may be associated with adverse psychiatric reactions. Advise patients and/or caregivers to immediately report any new or worsening behavioral or mood disturbances to their health care provider.
![](/images/a/af/Zilrettaifu.png)
Precautions with Alcohol
Alcohol-Triamcinolone acetonide (Zilretta) interaction has not been established. Talk to your doctor regarding the effects of taking alcohol with this medication.
Brand Names
- Zilretta
Look-Alike Drug Names
There is limited information regarding Triamcinolone acetonide (Zilretta) Look-Alike Drug Names in the drug label.
Drug Shortage Status
Drug Shortage
Price
References
The contents of this FDA label are provided by the National Library of Medicine.